Title:Progresses in Nano-Enabled Platforms for the Treatment of Vaginal
Disorders
Volume: 17
Issue: 3
Author(s): Riya Patel, Bindu Kumari Yadav and Gayatri Patel*
Affiliation:
- Department of Pharmaceutics, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology,
Changa, Gujarat 388421, India
Keywords:
Nanocarriers, vaginal disorders, targeted drug delivery, vaginal drug delivery, non invasive drug, therapeutic efficacy.
Abstract:
Background: The most common vaginal disorders are within the uterus. According to the
latest statistics, vaginal disorders occur in 50% to 60% of females. Although curative treatments rely
on surgical therapy, still first-line treatment is a non invasive drug. Conventional therapies are available
in the oral and parenteral route, leading to nonspecific targeting, which can cause dose-related side effects.
Vaginal disorders are localized uterine disorders in which intrauterine delivery via the vaginal
site is deemed the preferable route to mitigate clinical drug delivery limitations.
Objective: This study emphasizes the progress of site-specific and controlled delivery of therapeutics in
the treatment of vaginal disorders and systemic adverse effects as well as the therapeutic efficacy.
Methods: Related research reports and patents associated with topics are collected, utilized, and summarized
the key findings.
Results: The comprehensive literature study and patents like (US 9393216 B2), (JP6672370B2), and
(WO2018041268A1) indicated that nanocarriers are effective above traditional treatments and have
some significant efficacy with novelty.
Conclusion: Nowadays, site-specific and controlled delivery of therapeutics for the treatment of vaginal
disorders is essential to prevent systemic adverse effects and therapeutic efficacy would be more
effective. Nanocarriers have therefore been used to bypass the problems associated with traditional delivery
systems for the vaginal disorder.